Discovery and Crystallographic Studies of Nonpeptidic Piperazine Derivatives as Covalent SARS-CoV-2 Main Protease Inhibitors
- 7 December 2022
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 65 (24) , 16902-16917
Abstract
The spread of SARS-CoV-2 keeps threatening human life and health, and small-molecule antivirals are in demand. The main protease (Mpro) is an effective and highly conserved target for anti-SARS-CoV-2 drug design. Herein, we report the discovery of potent covalent non-peptide-derived Mpro inhibitors. A series of covalent compounds with a piperazine scaffold containing different warheads were designed and synthesized. Among them, GD-9 was identified as the most potent compound with a significant enzymatic inhibition of Mpro (IC50 = 0.18 μM) and good antiviral potency against SARS-CoV-2 (EC50 = 2.64 μM), similar to that of remdesivir (EC50 = 2.27 μM). Additionally, GD-9 presented favorable target selectivity for SARS-CoV-2 Mpro versus human cysteine proteases. The X-ray co-crystal structure confirmed our original design concept showing that GD-9 covalently binds to the active site of Mpro. Our nonpeptidic covalent inhibitors provide a basis for the future development of more efficient COVID-19 therapeutics.Keywords
Funding Information
- China Postdoctoral Science Foundation (2021M702003)
- Natural Science Foundation of Guangdong Province (2021A1515110740, ZR2020JQ31)
- Natural Science Foundation of Shandong Province (ZR2021ZD17)
- Volkswagen Foundation
- Foreign Cultural and Educational Experts Project (GXL20200015001)
This publication has 33 references indexed in Scilit:
- A Multipronged Approach Establishes Covalent Modification of β-Tubulin as the Mode of Action of Benzamide Anti-cancer ToxinsJournal of Medicinal Chemistry, 2020
- Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main proteaseNature Communications, 2020
- Characteristics of SARS-CoV-2 and COVID-19Nature Reviews Microbiology, 2020
- Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main proteaseScience, 2020
- Structure of Mpro from SARS-CoV-2 and discovery of its inhibitorsNature, 2020
- Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor bindingThe Lancet, 2020
- Targeting STING with covalent small-molecule inhibitorsNature, 2018
- A study of the reactivity of S(VI)–F containing warheads with nucleophilic amino-acid side chains under physiological conditionsOrganic & Biomolecular Chemistry, 2017
- A Novel Class of Highly Potent Irreversible Hepatitis C Virus NS5B Polymerase InhibitorsJournal of Medicinal Chemistry, 2012
- Halogen bonds in biological moleculesProceedings of the National Academy of Sciences, 2004